DE602005021159D1 - Bakteriophagen- und prophagen-proteine in der krebsgentherapie - Google Patents
Bakteriophagen- und prophagen-proteine in der krebsgentherapieInfo
- Publication number
- DE602005021159D1 DE602005021159D1 DE602005021159T DE602005021159T DE602005021159D1 DE 602005021159 D1 DE602005021159 D1 DE 602005021159D1 DE 602005021159 T DE602005021159 T DE 602005021159T DE 602005021159 T DE602005021159 T DE 602005021159T DE 602005021159 D1 DE602005021159 D1 DE 602005021159D1
- Authority
- DE
- Germany
- Prior art keywords
- polypeptide
- prophagen
- bacteriophage
- proteins
- cancer therapy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 108090000623 proteins and genes Proteins 0.000 title abstract 2
- 238000011275 oncology therapy Methods 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 title 1
- 241001515965 unidentified phage Species 0.000 title 1
- 229920001184 polypeptide Polymers 0.000 abstract 5
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 5
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 5
- 210000004102 animal cell Anatomy 0.000 abstract 2
- 230000030833 cell death Effects 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 230000001939 inductive effect Effects 0.000 abstract 2
- 230000002401 inhibitory effect Effects 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 230000035755 proliferation Effects 0.000 abstract 2
- 108091026890 Coding region Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 150000007523 nucleic acids Chemical group 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Tropical Medicine & Parasitology (AREA)
- Gastroenterology & Hepatology (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Hematology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP04017128A EP1618886A1 (de) | 2004-07-20 | 2004-07-20 | Bacteriophage- und Prophage-Proteine in der Krebs-Gen-Therapie |
| PCT/EP2005/053533 WO2006008312A1 (en) | 2004-07-20 | 2005-07-20 | Bacteriophage and prophage proteins in cancer gene therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE602005021159D1 true DE602005021159D1 (de) | 2010-06-17 |
Family
ID=34925838
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE602005021159T Expired - Fee Related DE602005021159D1 (de) | 2004-07-20 | 2005-07-20 | Bakteriophagen- und prophagen-proteine in der krebsgentherapie |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20090117084A1 (de) |
| EP (2) | EP1618886A1 (de) |
| JP (1) | JP2008506411A (de) |
| KR (1) | KR20070036185A (de) |
| CN (1) | CN1988913A (de) |
| AT (1) | ATE466588T1 (de) |
| AU (1) | AU2005263771A1 (de) |
| CA (1) | CA2572832A1 (de) |
| DE (1) | DE602005021159D1 (de) |
| EA (1) | EA012120B1 (de) |
| NO (1) | NO20070485L (de) |
| NZ (1) | NZ553196A (de) |
| WO (1) | WO2006008312A1 (de) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011103567A2 (en) * | 2010-02-22 | 2011-08-25 | Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center | Peptides and methods for inducing cell death |
| CN102994456B (zh) * | 2011-09-15 | 2016-06-15 | 蔡志明 | 一种人工合成的s13噬菌体及其应用 |
| EP3810163A1 (de) * | 2018-06-19 | 2021-04-28 | GlaxoSmithKline Biologicals SA | Immunogene zusammensetzung |
| WO2022261498A1 (en) * | 2021-06-11 | 2022-12-15 | Integrated Pharma Services, Llc | Device and methods for acne therapeutics: antibacterial bacteriophages and engineered lysins |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6608187B2 (en) * | 2000-05-23 | 2003-08-19 | The Rockefeller University | C1 bacteriophage lytic system |
| US20030036643A1 (en) * | 2000-09-14 | 2003-02-20 | Jin Cheng He | Methods and compositions for the construction and use of fusion libraries |
| PL195815B1 (pl) * | 2002-08-05 | 2007-10-31 | Inst Immunologii I Terapii Dos | Sposób otrzymywania szczepu bakteriofaga o zwiększonym powinowactwie do komórek eukariotycznych, środki go zawierające i zastosowania bakteriofagów |
| WO2004046319A2 (en) * | 2002-11-14 | 2004-06-03 | Gangagen, Inc. | Bacteriophage having modified holin and uses thereof |
-
2004
- 2004-07-20 EP EP04017128A patent/EP1618886A1/de not_active Withdrawn
-
2005
- 2005-07-20 AU AU2005263771A patent/AU2005263771A1/en not_active Abandoned
- 2005-07-20 US US11/572,260 patent/US20090117084A1/en not_active Abandoned
- 2005-07-20 KR KR1020077003983A patent/KR20070036185A/ko not_active Application Discontinuation
- 2005-07-20 CA CA002572832A patent/CA2572832A1/en not_active Abandoned
- 2005-07-20 AT AT05772001T patent/ATE466588T1/de not_active IP Right Cessation
- 2005-07-20 JP JP2007521953A patent/JP2008506411A/ja active Pending
- 2005-07-20 EA EA200700346A patent/EA012120B1/ru not_active IP Right Cessation
- 2005-07-20 DE DE602005021159T patent/DE602005021159D1/de not_active Expired - Fee Related
- 2005-07-20 CN CNA2005800243303A patent/CN1988913A/zh active Pending
- 2005-07-20 NZ NZ553196A patent/NZ553196A/en not_active IP Right Cessation
- 2005-07-20 EP EP05772001A patent/EP1853291B1/de not_active Not-in-force
- 2005-07-20 WO PCT/EP2005/053533 patent/WO2006008312A1/en active Application Filing
-
2007
- 2007-01-25 NO NO20070485A patent/NO20070485L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EA200700346A1 (ru) | 2007-10-26 |
| EP1618886A1 (de) | 2006-01-25 |
| CA2572832A1 (en) | 2006-01-26 |
| NZ553196A (en) | 2009-08-28 |
| JP2008506411A (ja) | 2008-03-06 |
| NO20070485L (no) | 2007-04-13 |
| KR20070036185A (ko) | 2007-04-02 |
| CN1988913A (zh) | 2007-06-27 |
| EP1853291B1 (de) | 2010-05-05 |
| US20090117084A1 (en) | 2009-05-07 |
| AU2005263771A1 (en) | 2006-01-26 |
| WO2006008312A1 (en) | 2006-01-26 |
| EP1853291A1 (de) | 2007-11-14 |
| ATE466588T1 (de) | 2010-05-15 |
| EA012120B1 (ru) | 2009-08-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE481978T1 (de) | Zusammensetzungen und verfahren zur behandlung von herzkrankheiten | |
| MX344216B (es) | Productos geneticos expresados de forma diferencial en tumores y su uso. | |
| HUP0002095A2 (hu) | Vegyületek prosztatarák immunterápiás kezelésére és alkalmazásuk | |
| WO2007035922A3 (en) | Aptamers to the human il-12 cytokine family and their use as autoimmune disease therapeutics | |
| CY1108459T1 (el) | Ακτ-3 νουκλεϊκα οξεα, πολυπεπτιδια, και χρησεις αυτων | |
| MX2020009371A (es) | Composiciones y métodos para la reprogramación de tcr mediante el uso de proteínas de fusión. | |
| BRPI0509278A (pt) | polipeptìdeo isolado, molécula de ácido nucléico isolada, vetor, célula hospedeira isolada, linhagem de célula empacotadora, dispositivo celular biocompatìvel implantável, composição farmacêutica, uso do polipeptìdeo, ou da seqüência de ácido nucléico isolada, ou do vetor de expressão, ou de uma composição de células hospedeiras, ou de um dispositivo celular biocompatìvel implantável ou de uma linhagem de célula empacotadora, método de tratamento de uma condição patológica em um indivìduo, métodos para prevenir a apoptose em uma célula neuronal de mamìfero, para realçar a sobrevivência de uma célula neuronal de mamìfero, para gerar um neurÈnio, para expandir uma composição de células de mamìfero, e para diferenciar uma composição de células de mamìfero, anticorpo, e, imunoconjugado | |
| WO2005086835A3 (en) | Aptamers to the human il-12 cytokine family and their use as autoimmune disease therapeutics | |
| BRPI0515604A (pt) | método para o tratamento de células de cáncer e método de tratamento de uma doença imune relacionada | |
| DE69434926D1 (de) | Menschlicher gewebsinhibitor von metalloproteinase-4 | |
| DE69635349D1 (de) | Nukleotidsequenzen, proteine, medikamente und diagnoseagentien zur anwendung in krebsbehandlung | |
| DE602005021159D1 (de) | Bakteriophagen- und prophagen-proteine in der krebsgentherapie | |
| MXPA02008239A (es) | Gen humano de la esquizofrenia. | |
| AR053285A1 (es) | Tratamiento de enfemedades usando un sistema mejorado de expresion regulada | |
| ATE534902T1 (de) | Replikationsproteinn ciz1 | |
| NO20021146D0 (no) | Polymorfier i de humane CYP3A4- og CYP3A7-genene og deres anvendelse i diagnostiske og terapeutiske anvendelser | |
| DE602004007924D1 (de) | Thrombopoietinproteine mit verbesserten eigenschaften | |
| TW200716749A (en) | Interferon-beta gene therapy using an improved, regulated expression system | |
| WO2002014369A3 (en) | Human kininogen d5 domain polypeptides and their use | |
| WO2004113386A3 (en) | Modified hirudin proteins and t-cell epitopes in hirudin | |
| WO2006072601A3 (en) | THERAPEUTIC USE OF GROWTH FACTORS, NsG29 AND NsG31 | |
| WO2002038188A3 (de) | Verwendung der humanen lrp/mvp promotors für einen therapie-induzierbaren vektor | |
| ATE460673T1 (de) | Screeningverfahren zum identifizieren protektiver substanzen für die behandlung neurodegenerativer und/oder ischämischer erkrankungen | |
| WO2004049917A3 (en) | Methods of therapy and diagnosis using targeting of cells that express ly-9 | |
| TNSN06265A1 (en) | Aptamers to the human il-12 cytokine family and their use as autoimmune disease therapeutics |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8339 | Ceased/non-payment of the annual fee |